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Objective: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
process affecting upper and lower motor neurons as well as non-motor systems. In
this study, precentral and postcentral cortical thinning detected by structural magnetic
resonance imaging (MRI) were combined with clinical (ALS-specific functional rating
scale revised, ALSFRS-R) and neurophysiological (motor unit number index, MUNIX)
biomarkers in both cross-sectional and longitudinal analyses.
Methods: The unicenter sample included 20 limb-onset classical ALS patients
compared to 30 age-related healthy controls. ALS patients were treated with standard
Riluzole and additional long-term G-CSF (Filgrastim) on a named patient basis after
written informed consent. Combinatory biomarker use included cortical thickness of
atlas-based dorsal and ventral subdivisions of the precentral and postcentral cortex,
ALSFRS-R, and MUNIX for the musculus abductor digiti minimi (ADM) bilaterally.
Individual cross-sectional analysis investigated individual cortical thinning in ALS patients
compared to age-related healthy controls in the context of state of disease at initial MRI
scan. Beyond correlation analysis of biomarkers at cross-sectional group level (n = 20),
longitudinal monitoring in a subset of slow progressive ALS patients (n = 4) explored
within-subject temporal dynamics of repeatedly assessed biomarkers in time courses
over at least 18 months.
Results: Cross-sectional analysis demonstrated individually variable states of cortical
thinning, which was most pronounced in the ventral section of the precentral cortex.
Correlations of ALSFRS-R with cortical thickness and MUNIX were detected. Individual
longitudinal biomarker monitoring in four slow progressive ALS patients revealed evident
differences in individual disease courses and temporal dynamics of the biomarkers.
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Conclusion: A combinatory use of structural MRI, neurophysiological and clinical
biomarkers allows for an appropriate and detailed assessment of clinical state and course
of disease of ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive
neurodegenerative disorder affecting upper and lower motor
neurons as well as non-motor systems (1). The degeneration
of motor neurons results in muscular fasciculation, progressive
weakness, and eventual paralysis (2). Average survival in ALS
is 3–5 years, but patients evidently vary in phenotype and
disease progression (2, 3). The great clinical heterogeneity
in ALS is reflected by different phenotypes with variability
regarding the involvement of upper motor neuron (UMN)
and lower motor neuron (LMN) signs, site of onset (bulbar,
limb), rate of progression, and involvement of neurobehavioral
deficits (2, 4). Therefore, clinical and biological biomarkers
are helpful in describing disease severity and progression
(3).
Magnetic resonance imaging (MRI) has produced potential
biomarkers that clarify the role of brain structure and function
in the progress of the disease (5, 6). In structural morphometric
studies, cortical thickness compared to surface and volume
was most sensitive to disease-related changes (7). A variety
of studies investigating structural surface-based morphometry
showed reduced cortical thickness primarily in the precentral
cortex (8–16). Cortical thinning was not restricted to the primary
motor cortex. Several studies reported cortical thinning to
spread to non-motor cortex areas like the temporal, frontal,
parietal, and postcentral cortex (8, 10, 15). However, not
all published MRI studies detected alterations in the cortical
thickness (17) or cortical volume (18, 19) of the precentral
cortex of ALS patients. Essentially, precentral cortical thinning
was reported to be focal, and dependent on the clinical
phenotype, rate of progression, and age (8, 11, 13). Additionally,
several longitudinal MRI studies revealed no further cortical
thinning of the precentral cortex in the course of disease
(9, 14–17).
In addition to MRI, clinical and electrophysiological
biomarkers are among the most currently used and prominent
biomarkers (20). The widely used ALS-specific functional
rating scale revised (ALSFRS-R) and its subscales are correlated
with survival (3). However, correlations between precentral
cortical thickness and ALSFRS-R scores were rather weak
Abbreviations: ADM, abductor digiti minimi; ALS, amyotrophic lateral sclerosis;
ALSFRS-R, ALS-specific functional rating scale revised; CMAP, compound muscle
action potential; G-CSF, granulocyte-colony stimulating factor; LMN, lower motor
neuron;MNI,Montreal Neurological Institute; MPRAGE,magnetization prepared
rapid gradient echo sequence; MRI, magnetic resonance imaging; MUNE, motor
unit number estimation; MUNIX, motor unit number index; PoD, postcentral
dorsal; PoV, postcentral ventral; PreD, precentral dorsal; PreV, precentral ventral;
ROI, region of interest; SIP, surface interference pattern; SMN, sensorimotor
network; SMUP, single motor unit potential; UMN, upper motor neuron.
(10, 21) or not detected in several neuroimaging studies so
far (9, 12, 13, 16, 22). While MRI is considered a suitable
biomarker for UMN function, neurophysiological motor unit
number estimation (MUNE) and motor unit number index
(MUNIX) are treated as biomarkers for the estimation of
functional lower motor units (23, 24). MUNE is calculated
from the division of maximal compound muscle action
potential (CMAP) by the mean surface single motor unit action
potential (SMUP) (25). In contrast, MUNIX is derived from a
mathematical model based on CMAP and electromyographic
surface interference patterns (SIP) (26). MUNE and MUNIX
scores are inter-correlated in ALS patients (23). As the
acquisition of MUNIX is easier and less time consuming than
that of MUNE, MUNIX has become a promising biomarker
of motor unit loss (27, 28). MUNIX scores were correlated
with ALSFRS-R scores (26), but they declined faster than
ALSFRS-R scores over time in ALS patients (29). Only few
studies investigated the relationship between neurophysiological
biomarkers and cortical thickness and failed to find a significant
correlation with MUNE or other motor evoked potential
indices (21, 30). To our knowledge, no published study
investigated correlations between cortical thickness and MUNIX
as a biomarker potentially affected by both lower and UMN
function (23).
Aim of the study was to investigate individual states of
cortical thinning of the precentral and postcentral cortex in a
limb-onset ALS sample with respect to young-onset, and slow
disease progression. It is the first study to analyze combinatory
biomarker use of MRI cortical thickness, neurophysiological
MUNIX, and routine ALSFRS-R in both cross-sectional group
analysis of the whole sample, and in longitudinal monitoring
exploring differences in temporal dynamics between biomarkers
in a subgroup of slow progressive ALS patients.
MATERIALS AND METHODS
Participants
Cross-sectional group analysis included 20 limb-onset classical
ALS patients (5 females, M = 48 years, SD = 11) compared
to 30 age-related healthy controls (14 females, M = 45 years,
SD= 13). Mean age of ALS patients was lower than that reported
in other ALS studies, as the sample included several young-onset
patients. Mean ALSFRS-R score across all 20 patients at the time
point of first MRI scan was 36 score points (SD = 8; range:
23–48). The sample included both slow and fast progressive
ALS patients indicated by disease progression rates (M = 0.51,
SD = 0.27; range: 0.00–1.00). The presence of both UMN and
LMN signs in all patients allowed no clear differentiation inUMN
or LMN predominance of disease. Patients’ characteristics are
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TABLE 1 | Patients’ characteristics at baseline.
# Range of age ALSFRS-R [0 48] MUNIX
left




1 21–25 30 6.63 10.43 49 Arm 0.37
2 26–30 35 8.20 29.21 28 Arm 0.46
3 31–35 24 6.94 2.83 28 Leg 0.86
4 41–45 24 * * 28 Leg 0.86
5 41–45 41 54.12 38.00 19 Leg 0.37
6 41–45 28 4.85 0.70 38 Arm 0.53
7 41–45 46 * * 16 Arm 0.13
8 46–50 39 138.40 41.88 56 Leg 0.16
9 46–50 48 170.10 187.30 19 Leg 0.00
10 46–50 24 48.37 18.51 24 Arm 1.00
11 46–50 46 213.60 193.00 3 Leg 0.67
12 46–50 40 114.50 97.18 21 Leg 0.38
13 46–50 38 * * 25 Leg 0.40
14 51–55 42 27.25 21.62 7 Arm 0.86
15 51–55 35 * * 33 Leg 0.39
16 56–60 38 123.90 101.60 29 Leg 0.34
17 56–60 44 126.90 0.00 13 Leg 0.31
18 61–65 42 83.10 119.00 10 Leg 0.60
19 61–65 24 12.34 9.66 33 Leg 0.73
20 66–70 21 6.94 2.83 36 Leg 0.75
Summary of baseline characteristics of all 20 limb-onset ALS patients including age (in ranges of years), ALSFRS-R sum score upon initial MRI scan (48 in clinical non affected),
neurophysiological MUNIX scores for left and right ADM upon initial MRI scan, the length of time span between symptom onset and initial MRI scan in months, onset of disease (arm,
leg), and progression rate. In four out of 20 ALS patients (marked with *), neurophysiological assessment was still conducted using MUNE technique (patient 4: left MUNE = 2, right
MUNE = 1; patient 7: left MUNE =3, MUNE right = 77; patient 13: left MUNE = 275, right MUNE = 85; patient 15: left MUNE = 240, right MUNE = 120). No MUNIX scores were
obtained in these four patients. Progression rates were calculated by [48-ALSFRS-R sum score/months since symptom onset; see (8)]. Neuropsychological assessment using the
Edinburgh Cognitive and Behavioral ALS Screen (ECAS) was conducted only in patient 3 (129/136 score points) and patient 9 (100/136 score points).
summarized in Table 1. These included age (in ranges of years),
ALSFRS-R sum scores and neurophysiological MUNIX scores
for left and right ADM upon initial MRI scan, time interval
between symptom onset and initial T1 MRI scan (in months),
onset of disease (arm, leg), and progression rates [(48-ALSFRS-
R)/months since symptom onset] (8). Genetic background of
ALS was exhibited in one patient only (patient 8). All other
patients were diagnosed as sporadic ALS.
All patients received standard Riluzole treatment and
additional G-CSF (granulocyte-colony stimulating factor,
Filgrastim) treatment on a named patient basis. Application
modes and doses of G-CSF were individually adapted, treatment
duration was up to 7 years. For safety and monitoring of
progression, structural MRI and MUNIX were assessed every
3 months. ALSFRS-R scores were acquired monthly, but were
integrated in the analysis only at the time points of MRI
scanning. MRI cortical thickness was combined with ALSFRS-R
sum scores, and MUNIX scores for left and right ADM in
both cross-sectional analysis and longitudinal biomarker
monitoring.
The unicenter project was carried out in accordance with
the Declaration of Helsinki (31) and approved by the ethics
committee at the University of Regensburg (ethics approval:
15-101-0106). Written informed consent was obtained prior to
participation in all participants.
Data Acquisition
Structural MRI was conducted at a 1.5 Tesla clinical scanner
(Aera, Siemens Medical, Erlangen, Germany). For each patient,
a high-resolution T1-weighted structural scan was obtained
by a magnetization prepared rapid gradient echo sequence
(MPRAGE; time-to-repeat TR: 2220ms, time-to-echo TE:
5.97ms, flip angle FA: 15◦, voxel size: 1 × 1 × 1 mm3, field of
view FOV: 256× 256 mm², 176 sagittal slices covering the whole
brain).
MUNIX estimates the number of motor units in a muscle by
a mathematical algorithm involving both the compound muscle
action potentials (CMAP) and the continuous electromyographic
surface interference pattern (SIP) of the muscles (23, 27). In
contrast to original MUNIX, MUNIX recordings of this project
implicated continuous SIP recordings during increasing muscle
contraction. SIP data were modified by baseline correction,
filter settings, rectifications, and SIP intervals. Artifacts were
corrected by exclusion of SIP intervals below a specified baseline
threshold. As MUNIX was introduced more recently as a
neurophysiological biomarker, four out of 20 ALS patients
received the assessment of MUNE only (see Table 1).
MRI Data Preprocessing
T1-weighted structural images were reconstructed by Freesurfer
software version 5.3 (Martinos Center for Biomedical Imaging,
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FIGURE 1 | Definition of regions of interest. (A) Precentral (red) and
postcentral (blue) cortex were identified by the Desikan-Killiany parcellation
atlas (34). (B) The resting-state-fMRI based atlas of Yeo et al. (35) was used to
define dorsal (marine blue) and ventral (brown) segments of the sensorimotor
network (SMN). (C) Final subdivision of the precentral and postcentral cortex
into dorsal and ventral segments resulted in four ROIs (precentral dorsal,
precentral ventral, postcentral dorsal, postcentral ventral) in both left and right
hemisphere. ROIs were mapped upon the Freesurfer average brain surface.
Charlestown, MA). The reconstruction procedure included
automatic segmentation of gray matter and subcortical white
matter (32) and tessellation and registration of the cortical
surface to a spherical atlas (33). For group analysis, T1-
weighted images of the 20 individual patients’ brains were
registered to the Freesurfer average structural brain by using the
Freesurfer linear and non-linear image registration tools (FLIRT,
FNIRT).
ROI Definition
Cortical thickness analysis focused on precentral and
postcentral regions of interest (ROI) as defined by the
Desikan-Killiany parcellation atlas [(34); see Figure 1A].
Dorsal and ventral subdivisions of the sensorimotor
network were defined by a resting-state-functional MRI
(fMRI) data-based atlas (35) in volumetric MNI (Montreal
Neurological Institute) space. These ROIs were subsequently
registered to the Freesurfer volumetric space and then to
the Freesurfer average brain surface (see Figure 1B). As
all ROIs were mapped upon the Freesurfer average brain
space, ROIs were identically sized in each patient and healthy
control.
Computation of Cortical Thickness
Cortical thickness was computed according to a workflow
recommended by Freesurfer software. Individual surface-based
cortical thickness data were mapped upon the Freesurfer average
brain surface. By the use of a segmentation statistical tool
of Freesurfer software, cortical thickness in each of the four
ROIs (PreD: precentral dorsal, PreV: precentral ventral, PoD:
postcentral dorsal, PoV: postcentral ventral, see Figure 1C) was
calculated and extracted as a mean value across vertices.
Cross-Sectional Group Analysis
Group-analysis of mean cortical thickness was conducted using
a repeated measures ANOVA with the within-subject factors
region (PreD, PreV, PoD, PoV) and hemisphere (left vs. right),
and the between-subject factors group (ALS vs. controls), gender
(male vs. female), and the covariate age. Differences in cortical
thickness between regions were investigated by paired t-tests
and differences between patients and controls were analyzed
using independent-samples t-tests. T-tests were corrected by
Bonferroni correction. Correlation analyses were conducted to
investigate relations between cortical thickness, ALSFRS-R sum
scores and subscores, and MUNIX by the Bravais-Pearson
correlation coefficient. Significance level was set to p < 0.05.
Multiple comparison errors were controlled by Bonferroni
correction procedure in post-hoc analyses.
Individual Cortical Thickness Analysis
In addition to cross-sectional group analysis, this project focused
on the interindividual variability of cortical thinning. For this
purpose, we compared the cortical thickness of all 20 patients
to age-related controls, resulting in individual z-transformed
deviations of cortical thickness from healthy control level. As
age effects on cortical thickness are well described (36), ALS
patients were compared to one out of two possible age groups.
Based on the mean age of ALS patients, the 30 healthy controls
were differentiated into two comparably sized subgroups (1: age
<48 years, n = 17; 2: age ≥48 years, n = 13). Furthermore,
z-transformed deviations of cortical thickness from healthy
controls as well as biomarkers MUNIX and ALSFRS-R were
monitored in four individual slow progressive ALS patients over
a time course of at least 18 months (patient 1, 2, 8, 9, see Table 1).
All other patients exhibited MRI time courses of a maximum of 9
months only (3 scans: n = 2; 2 scans n = 6; 1 scan: n = 8) due to
high disability and lack of T1 MRI data.
RESULTS
Cross-Sectional Group Analysis
As Mauchly’s test indicated that the assumption of sphericity
was violated [χ ²(5) = 22.42, p < 0.001], degrees of freedom
were corrected using Greenhouse-Geisser estimates of sphericity
(ε = 0.79). Cortical thickness was not significantly different
between patients and healthy controls [F(1, 45)= 1.314; p= 0.258]
at cross-sectional group level. Cortical thickness significantly
varied across cerebral regions [F(3, 135) = 23.351, p < 0.001]
and with respect to age [F(1, 45) = 21.776, p < 0.001].
Cortical thickness was significantly higher in precentral than in
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FIGURE 2 | Precentral and postcentral cortical thickness. Cross-sectional analyses of cortical thickness of ALS patients (n = 20) and healthy controls (n = 30). (A)
Precentral cortical thickness averaged across left (lh) and right (rh) hemisphere was significantly higher than postcentral cortical thickness in both ALS patients and
healthy controls. (B) Cortical thickness of ventral segments of both precentral (PreV) and postcentral (PoV) cortex were similarly higher than in dorsal segments (PreD,
PoD) in both ALS patients and healthy controls. Hemispheric differences were detected only in the precentral (C) and precentral ventral cortex (D) of healthy controls.
Significance level was set to p < 0.05. Bonferroni correction was used for multiple comparisons. Lh, left hemisphere; Rh, right hemisphere; PreV, precentral ventral;
PreD, precentral dorsal; PoV, postcentral ventral; PoD, postcentral dorsal. Asterisks refer to the height of p-value: *p < 0.05, ***p < 0.001.
postcentral regions in both ALS patients [T(19) = 8.584, p< 0.05,
corrected], and healthy controls [T(29) = 16.521, p < 0.05,
corrected] (Figure 2A). Ventral subdivisions of precentral
and postcentral cortex showed greater cortical thickness than
dorsal subdivisions in both ALS patients [T(19) = 9.906,
p < 0.05, corrected] and healthy controls [T(29) = 12.389;
p < 0.05, corrected] (Figure 2B). The ANOVA revealed no
significant main effect of hemisphere, as significant hemispheric
differences in cortical thickness were restricted to the precentral
[T(29) = 3.445, p < 0.05, corrected] (Figure 2C) and precentral
ventral cortex [T(29) = 3.596, p < 0.05, corrected] of healthy
controls (Figure 2D). ALSFRS-R sum scores correlated with
cortical thickness of the precentral ventral cortex (r = 0.570, p =
0.009) and the postcentral ventral region (r = 0.481, p = 0.032).
Cortical thickness did not significantly correlate with MUNIX
scores for left and right ADM in any ROI. MUNIX scores for the
left (r= 0.767, p< 0.05, corrected) and right (r= 0.791, p< 0.05,
corrected) ADM correlated with ALSFRS-R sum scores. Highest
correlations of cortical thickness with ALSFRS-R subscores were
found for turning (PreV: r = 0.501, p = 0.024; PoV: r = 0.652,
p = 0.002), walking (PoV: r = 0.603, p = 0.005), and cutting
(PreV: r = 0.453, p = 0.045). MUNIX scores predominantly
correlated with ALSFRS-R subscores on handwriting (left ADM:
r = 0.637, p = 0.008; right ADM: r = 0.678, p = 0.005),
cutting (left ADM: r = 0.840, p < 0.001; right ADM: r = 0.834,
p< 0.001), dressing (left ADM: r = 0.793, p< 0.001, right ADM:
r = 0.806, p < 0.001), turning (left ADM: r = 0.609, p = 0.012;
right ADM: r = 0.663, p= 0.007), and climbing stairs (left ADM:
r = 0.563, p = 0.023; right ADM: r = 0.611, p = 0.016). ALS
patients were separated post-hoc in arm-onset (n = 7) and leg-
onset (n = 13) groups. Arm-onset patients showed significantly
lower MUNIX scores for ADM (left: M = 19, SD = 19; right:
M = 16, SD= 11) than leg-onset patients (left:M = 95, SD= 69;
right: M = 72, SD = 72) [left ADM: T(14) = −3.399, p < 0.05,
corrected; right ADM: T(14) = −2.506; p = 0.029]. Arm-onset
and leg-onset patients did not significantly differ in disease
progression, ALSFRS-R sum scores and subscores.
Variability of Cortical Thinning
Thirty healthy controls were differentiated into two groups of
age (1. age <48 years, 2. age ≥48 years, see section Individual
Cortical Thickness Analysis). In each of the two subgroups,
means of cortical thickness of all precentral and postcentral ROIs
(see Table 2) were calculated. These mean values were used as
reference values for the calculation of z-transformed deviations
of ROI-specific cortical thickness of individual ALS patients (for
patient numbers see Table 1) from healthy control level.
Cortical thickness alterations below at least one deviation
from healthy control level were detected in eleven out of twenty
patients (patients 1, 2, 3, 4, 6, 10, 14, 16, 18, 19, 20) andmarginally
indicated in two patients (patients 5, 9). Cortical thinning was
primarily observed in the precentral cortex, especially in the
ventral segment (Figure 3A). Most pronounced cortical thinning
in all precentral ROIs was detected in patient 10 and patient 19.
Leg-onset patient 19 was characterized by older age (range: 61–
65 years), low ALSFRS-R score (24 score points), low MUNIX
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TABLE 2 | References values of cortical thickness.
Lh PreV (mm) Rh PreV (mm) Lh PreD (mm) Rh PreD (mm) Lh PoV (mm) Rh PoV (mm) Lh PoD (mm) Rh PoD (mm)
1 M 2.542 2.442 2.106 2.068 2.276 2.205 1.804 1.798
SD 0.205 0.139 0.194 0.158 0.165 0.188 0.158 0.163
2 M 2.249 2.132 1.827 1.807 2.072 2.016 1.663 1.584
SD 0.184 0.275 0.242 0.232 0.198 0.244 0.141 0.145
Cortical thickness (mm) of healthy control participants subdivided into two age groups (1: age <48 years, 2: age ≥48 years). Mean age of the two subgroups: Group 1: M = 36, SD = 7,
n = 17; Group 2: M = 52, SD = 15, n = 13. Lh, left hemisphere; Rh, right hemisphere; PreV, precentral ventral; PreD, precentral dorsal; PoV, postcentral ventral; PoD, postcentral
dorsal.
FIGURE 3 | Individual variability of cortical thinning in ALS patients. Z-transformed deviation of cortical thickness from age-related healthy controls (see Table 2) in all
20 individual ALS patients. Patient numbers refer to Table 1. Patients were sorted by age. Z-transformed deviations of cortical thickness were considered relevant at
least one deviation from healthy controls. (A) Individual variability of cortical thickness of the left (lh, yellow) and right (rh, red) precentral ventral (PreV) and left (lh, pink)
and right (rh, purple) precentral dorsal (PreD) ROIs. (B) Deviations of individual cortical thickness of the left (lh, light green) and right (rh, dark green) postcentral ventral
(PoV) and the left (lh, bright blue) and right (rh, dark blue) postcentral dorsal (PoD) region in the same 20 individual patients. Precentral (A) and postcentral (B) ROIs
were visualized upon the Freesurfer average brain surface. Lh, left hemisphere; Rh, right hemisphere; PreV, precentral ventral; PreD, precentral dorsal; PoV,
postcentral ventral; PoD, postcentral dorsal.
scores of ADM, and high disease progression rate (0.73). Patient
10 was much younger (range: 46–50 years), but showed low
ALSFRS-R score (24 score points), and the highest progression
rate (1.00) of the entire patient sample (see Table 1). The two
youngest ALS patients (patients 1–2, age ranges: 21–25 and 26–30
years) shared similar patterns of cortical thinning, similar mode
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of disease (arm-onset), low ALSFRS-R scores, lowMUNIX scores
for ADM, and similar disease progression rates (see Table 1,
see Figure 3A). Cortical thinning in the postcentral cortex was
detected in four patients (patients 9, 10, 19, 20; Figure 3B).
Three out of these four patients also exhibited evident precentral
cortical thinning. Leg-onset patient 9 stood out of the sample
with the highest ALSFRS-R score, high MUNIX scores for ADM,
lowest progression rate (0.00), and more pronounced cortical
thinning of the postcentral cortex than of the precentral cortex.
Increased levels of cortical thickness above healthy control
level were more prominent in the postcentral cortex than in
the precentral cortex. Seven patients exhibited unremarkable
levels of cortical thickness (patients 7, 8, 11, 12, 13, 15, 17).
Six (patients 7, 8, 12, 13, 15, 17) out of these seven patients
exhibited disease progression rates less or equal to 0.40 (see
Table 1).
Longitudinal Monitoring of Cortical
Thickness, ALSFRS-R, and MUNIX
Repeated long-term follow-up T1MRI data exceeding 18 months
were available in two leg-onset patients (patients 8, 9) and two
arm-onset patients (patients 1, 2). The four patients presented
different initial levels and longitudinal courses of ALSFRS-R
sum scores (Figure 4A), MUNIX scores (Figure 4B), and cortical
thickness alterations (Figures 4C–F). Both patients 1 and 2 have
in common young-onset (21–30 years), arm-onset diagnosis, low
levels of ALSFRS-R scores (patient 1: 30 score points, patient
2: 35 score points) upon first MRI scan, low MUNIX scores
for left and right ADM (see Table 1), and similar progression
rates (patient 1: 0.37, patient 2: 0.46). In both patients, ALSFRS-
R sum scores decreased over time (patient 1: blue; patient
2: green; Figure 4A). In contrast, MUNIX for left and right
ADM stagnated at low level (patient 1: blue; patient 2: green;
FIGURE 4 | Individual and long-term biomarker monitoring over at least 18 months. Arm-onset and young-onset patients (patient 1, 2) showed higher progression
rates (see Table 1) than leg-onset similarly aged patients 8 and 9. Patient 9 (yellow), Patient 8 (red), Patient 2 (green), patient 1 (blue) are sorted based on the initial
levels of ALSFRS-R sum scores. (A) Courses of ALSFRS-R sum scores of the four individual patients starting at different baseline values and developed differently
over the measured time span. (B) Long-term courses of MUNIX scores for the left and right ADM of the same four patients. Individual long-term monitoring of cortical
thickness of these four patients in the precentral ventral (PreV, C) and dorsal cortex (PreD, D) and postcentral ventral (PoV, E) and dorsal (PoD, F) cortex of both
hemispheres. Individual cortical thickness is z-transformed to age-related healthy control level (see Table 2). Lh, left hemisphere; Rh, right hemisphere.
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Figure 4B). Cortical thickness of the precentral ventral cortex
persisted below healthy control level over time in both patients
(patient 1: blue, patient 2: green; Figure 4C). Cortical thickness of
the precentral dorsal cortex decreased below healthy control level
in patient 1 in the longitudinal course (Figure 4D). No cortical
thinning consistently below healthy control level was found for
the postcentral ROIs in both patients 1 and 2 (Figures 4E,F).
Patient 8 and 9 (both aged 46–50 years) were diagnosed with leg-
onset disease and obtained high ALSFRS-R sum scores at time
point of initial MRI scan (Table 1). Progression rates of patient
8 (0.16) and 9 (0.00) were much lower than for patients 1 and
2. In both patients, ALSFRS-R sum scores declined over time
(patient 8: red, patient 9: yellow, Figure 4A). MUNIX scores of
patient 9 similarly decreased for the left and right ADM (yellow,
Figure 4B). In patient 8, MUNIX scores for the left ADM started
at much higher level than for the right ADM and showed a more
pronounced decline of scores over time (red, Figure 4B). Patient
8 exhibited progressive cortical thinning only in the postcentral
ventral cortex (Figure 4E). In patient 9, cortical thinning of the
right precentral dorsal cortex spread to the left hemisphere over
the time course (yellow, Figure 4D). Cortical thickness of the
postcentral dorsal cortex further decreased over time (yellow,
Figure 4F). Despite fluctuations, ventral sections of precentral
and postcentral cortex of patient 9 persisted at healthy control
level (yellow, Figures 4C,E).
DISCUSSION
Cortical thinning was heterogenous and most pronounced
in the precentral ventral cortex. ALSFRS-R sum score was
associated with both cortical thickness and MUNIX scores.
Individual longitudinal monitoring of clinical ALSFRS-R,
neurophysiological MUNIX, and MRI cortical thickness
indicated both interindividual differences among ALS patients
as well as differences in temporal dynamics between biomarkers
over the course of disease.
Cortical Thickness of the Precentral and
Postcentral Cortex
Cortical thickness was highly age-dependent and significantly
different between precentral and postcentral cortex as well
as between ventral and dorsal subdivisions of precentral and
postcentral cortex. Postmortem (37) and MRI (38, 39) studies
showed approximately 1.5 times greater cortical thickness of the
precentral compared to the postcentral cortex. The only study
addressing gradients of postcentral cortical thickness in humans
(40) reported greatest cortical thickness in the area defined as
ventral segment in our study. Age effects on precentral and
postcentral cortical thickness have been well described (36).
Variability of Cortical Thinning
Individual cross-sectional analysis revealed heterogenous
individual states of cortical thinning, which was more
pronounced in the precentral than in the postcentral cortex.
Postcentral cortical thinning was only present in four patients.
Three out of these four patients also showed pronounced
cortical thinning of the precentral cortex. These observations are
consistent with studies reporting postcentral atrophy was rather
less prominent or not detectable (12, 41). Instead, postcentral
atrophy was discussed to result from the spread of cortical
degeneration in the course of disease (41, 42). With respect
to the spread of disease, interestingly, individual longitudinal
analysis revealed that patient 8 developed postcentral cortical
thinning despite lack of precentral cortical thinning. Cortical
thinning was most pronounced in the ventral segment of the
precentral cortex. The precentral ventral cortex as defined
here was also reported to exhibit alterations in ALS patients
in other studies (14, 43, 44). Seven out of twenty patients
exhibited no indications of cortical thinning. This finding is
supported by a meta-analysis reporting cortical atrophy only in
a percentage of ALS cases (45) and other MRI studies failing to
find alterations in the precentral cortex of ALS patients (17–19).
The lack of cortical thinning in ALS patients may be explained
by low progression rates and young-onset. Cortical thinning
was primarily observed in ALS patients with faster progression
or advanced stage of disease (46). Six out of seven patients
exhibiting no indications of cortical thinning were characterized
with disease progression rates less or equal to 0.40. Moreover,
the ALS sample of the current study was much younger than
ALS patients involved in most MRI studies (8, 13, 17, 43, 47, 48).
Individual cross-sectional analysis also revealed enhanced levels
of cortical thickness predominantly in the postcentral cortex.
Future studies may investigate if enhanced levels of cortical
thickness may be associated with processes of neuroplasticity or
treatment effects. Finally, heterogeneous alterations in cortical
thickness (including increases and decreases) argue for the
need of individual perspective on ALS patients beyond group
averages (6).
Longitudinal Monitoring of Cortical
Thickness, ALSFRS-R, and MUNIX
Longitudinal monitoring of cortical thickness in four patients
revealed differences in temporal dynamics of clinical ALSFRS-R,
neurophysiological MUNIX, and MRI cortical thickness in the
same individual patients. The long-term biomarker monitoring
was limited to the patients who survived for longer periods
of time and who underwent more than three MRI scans. All
other patients of the sample received three MRI scans or less
due to short survival or lack of scan capability. Similar to
Abhinav et al. (49), patients showed very different baseline
levels and various progression types of ALSFRS-R sum scores
over time. While the decline of high-level ALSFRS-R sum
scores of patient 9 (ALSFRS-R baseline: 48) was evidently
observable, changes in ALSFRS-R sum scores of progressed
stage patient 1 (ALSFRS-R baseline: 30) were less evident. These
observations are consistent with ALSFRS-R being considered
to be less sensitive for short-term time windows and slow
disease progression (3, 24, 50). ALSFRS-R is also regarded as
a rather general severity summary scale without sensitivity for
mode of disease (17, 29). The unspecific character of ALSFRS-
R may also explain why correlations between ALSFRS-R and
cortical thickness were weak or not detectable (9, 15, 21).
In contrast to ALSFRS-R, MUNIX significantly differentiated
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between arm and leg-onset of disease. Corresponding to
Grimaldi et al. (26), MUNIX scores significantly correlated
with ALSFRS-R scores, but showed much faster longitudinal
dynamics than ALSFRS-R scores as reported by Neuwirth
et al. (29). Once at very low level MUNIX scores stagnated
across time in arm-onset patients 1 and 2. The phenomenon
of a floor effect of MUNIX measurements at low level in
completely wasted muscles was described by Neuwirth et al.
(51). In contrast, higher level MUNIX scores for ADM in
leg-onset patients 8 and 9 showed a fast decrease over
time. Consistent with these observations, clinical markers are
considered to be more sensitive to changes than MRI markers
(17). Although MUNIX is considered a candidate biomarker
like MUNE for LMN function (24), MUNIX scores may be
influenced by both lower and UMN function (23). Existing
studies investigating correlations of cortical thickness to MUNE
or other neurophysiological techniques failed to find significant
correlations (21, 30). As the first study combining MRI cortical
thickness withMUNIX, we also found no significant correlations.
Differences in both individual state of disease and within-subject
temporal dynamics of various biomarkers may explain the
difficulty to find significant correlations inmultimodal biomarker
use.
Methodological Limitations
Some methodological limitations need to be considered. First,
the sample size was limited to 20 patients. As ALS MRI studies
suffer from high costs and high drop-out rates due to increasing
disability of patients (50), many published unicenter ALS MRI
studies included samples smaller than 20 ALS patients (12, 41, 52,
53). Second, the MRI magnetic field strength was 1.5T. Although
MRI magnetic field strength of 3T may have been beneficial, 1.5T
still was sufficient for the detection of gray matter alterations in
ALS MRI studies (11, 12, 22, 41, 54). Third, by the use of a more
conservative ROI based approach than a vertex-based approach,
the study may have failed to detect very focal cortical thinning
inside of the ROIs. However, this approach did not only reduce
the influence of false positive results but still successfully detected
cortical thinning. Fourth, MUNIX scores were not assessed in
leg muscles. However, this study is the first cross-sectional and
longitudinal study combining cortical thickness analysis with
both ALSFRS-R and MUNIX with respect to the individual
patient. Fifth, longitudinal monitoring of biomarkers was limited
to four patients of the sample due to high disability (n= 6), death
(n = 4), lack of T1 data (n = 6). Still, our long-term biomarker
monitoring analysis is unique, as to our knowledge, none of the
published longitudinal MRI studies showed longitudinal courses
of both MRI cortical thickness and MUNIX biomarkers using
as many repeated measures in a time course longer than 18
months as presented in the current study. Moreover, most MRI
studies focused on group analysis irrespective of the individual
patient (9, 10, 14–17), although the individual perspective has
been increasingly demanded in ALS neuroimaging research (6,
24, 55, 56).
CONCLUSIONS
The present study demonstrated that MRI is a potential
biomarker for the differentiation of individual states of cortical
thinning in an ALS sample including young-onset and slow
progressive patients. Longitudinal monitoring of MRI, clinical,
and neurophysiological biomarkers in the same patient reveal
substantial differences in temporal dynamics. Combinatory
biomarker use contributes a substantial gain of information
about individual state of disease beyond group averages. Future
studies may expand the idea of combining neuroimaging
techniques with other clinical or molecular biomarkers to deepen
our understanding of multisystem/multifactorial ALS disease
progression.
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